Activating mutations of KRAS and BRAF genes are detected in up to 60% of CRC, not long after APC or β-catenin mutations, and contribute to enforce the oncogenic signaling of β-catenin also conveying an invasive and metastatic behavior in cancer cells [2]. Here, KRAS is linked to colorectal carcinoma.